The U.S. Court of Appeals for the Federal Circuit renders a split decision regarding sham patent litigation (Tyco Healthcare / Mutual Pharmaceutical)

The U.S. Court of Appeals for the Federal Circuit has remanded for further consideration antitrust claims accusing a patent holder of filing a sham infringement suit and a sham citizen petition with the Federal Drug Administration. The case is Tyco Healthcare Group LP v. Mutual Pharmaceutical Co. (Fed. Cir., Aug. 6, 2014). This split decision has significant implications both for patent holders planning to assert infringement claims and for infringement defendants considering antitrust counterclaims. Background Sandoz Limited applied for several patents directed to formulations and features of, and methods of treatment with, temazepam, a drug used to treat insomnia. In 2001, Tyco Healthcare Group LP and Mallinckrodt, Inc. ("Tyco") acquired the patents from Sandoz, and currently

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Geoffrey D. Oliver, Michelle K. Fischer, Kevin D. McDonald, The U.S. Court of Appeals for the Federal Circuit renders a split decision regarding sham patent litigation (Tyco Healthcare / Mutual Pharmaceutical), 6 August 2014, e-Competitions Bulletin August 2014, Art. N° 68720

Visites 91

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues